Illumina, Inc. $ILMN Stock: Oregon Public Employees Retirement Fund Decreases Stake

Posted by Brenda Bartman on Nov 6th, 2026

Oregon Public Employees Retirement Fund lowered its holdings in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 40.5% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 18,600 shares of the life sciences company’s stock after selling 12,667 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Illumina were worth $5,090,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ILMN. BlackRock Inc. bought a new position in Illumina in the 2nd quarter worth approximately $3,374,423,000. Primecap Management Co. CA bought a new stake in shares of Illumina in the second quarter valued at approximately $617,981,000. Jupiter Topco LLC bought a new stake in shares of Illumina in the second quarter valued at approximately $358,652,000. WCM Investment Management LLC boosted its position in shares of Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after acquiring an additional 1,851,848 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Illumina in the second quarter worth $293,846,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

ILMN has been the topic of a number of research reports. Piper Sandler boosted their target price on shares of Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, September 28th. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Sunday, October 11th. Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 1st. JPMorgan Chase & Co. decreased their price target on shares of Illumina from $320.00 to $300.00 and set an “overweight” rating on the stock in a research report on Friday, October 30th. Finally, Barclays raised their price target on shares of Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a research report on Wednesday, October 7th. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Illumina presently has a consensus rating of “Hold” and a consensus price target of $244.24.

Check Out Our Latest Report on Illumina

Illumina Trading Down 8.2%

Shares of ILMN opened at $208.00 on Friday. The stock’s 50-day moving average price is $249.44 and its 200 day moving average price is $177.79. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $31.45 billion, a price-to-earnings ratio of 35.80, a P/E/G ratio of 3.08 and a beta of 1.46. Illumina, Inc. has a 12-month low of $112.65 and a 12-month high of $309.35.

Illumina (NASDAQ:ILMN – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The company had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.15 billion. During the same quarter last year, the company earned $1.34 EPS. The company’s quarterly revenue was up 4.2% on a year-over-year basis. As a group, research analysts predict that Illumina, Inc. will post 5.43 earnings per share for the current year.

Insider Activity

In related news, Director Keith Meister sold 50,000 shares of the company’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $227.17, for a total value of $11,358,500.00. Following the completion of the transaction, the director directly owned 488,917 shares in the company, valued at approximately $111,067,274.89. This represents a 9.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 1,601,541 shares of company stock worth $354,755,291 in the last quarter. Insiders own 2.90% of the company’s stock.

About Illumina

(Free Report)

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.